BXTA logo

PrecisionPoint™

Sistema de acceso transperineal - revolución en la metodología para obtener biopsias de próstata

La misión de BXTA es formar al mundo sobre los beneficios de la biopsia de próstata LATP: biopsias transperineales realizadas sin anestesia local.

As the sole distributor, outside North America, for the PrecisionPoint™ single use device, that enables LATP, and alongside international partners that including organisations such as the British Association of Urological Surgeons, The Royal Society of Medicine, Prostate Cancer UK, The British Association of Urological Nurses and entre otros, nuestra misión es erradicar el método estándar actual de pronóstico de cáncer ‘de facto’: el ultrasonido transrectal (TRUS) guiada o biopsia transrectal.

PP Device gif

Está demostrado que la detección precoz y exacta del cáncer de próstata amplia las opciones de tratamiento a los pacientes, mejorando los resultados a la vez que reduce los efectos adversos.

Yet, TRUS biopsy has a high risk of infection, including patients given prophylaxis medication. In a recent study, 7 of 564 patients who received TRUS were admitted to the hospital for infection within the first 7 days, compared to 1 of 562 patients for LATP. At 4 months, 13 patients who received TRUS had required hospital admission, compared to 6 patients who had received LATP1. The alternative transperineal or template (TP) biopsy has, in the past, typically only been available to men at greater risk of infection from certain medical conditions, and had to be done under general anaesthetic because of the need for multiple biopsy punctures

The PrecisionPoint™ Transperineal Access System is now revolutionising the methodology for obtaining prostate biopsies. Not only does it take full advantage of the transperineal path, decreasing risk of infections, it allows for more thorough sampling of all regions of the prostate including those difficult to access with the transrectal approach2

PrecisionPoint™ provides a free-hand experience for HCP to operate in local anaesthetic settings, potentially aiding hospitals with limited resources.

Beneficios

  • Manos libres cómodo y fácil de aprender
  • Decreases risk of sepsis over the transrectal approach, removing the necessity for routine antibiotic use thereby decreasing the risks of the spread of antibiotic-resistant micro-organisms3
  • Permite realizar el muestreo en patrón sin necesidad de obtener el patrón o pasos y una unidad de estabilización4
  • Se realiza con anestesia local, por lo que puede llevarse a cabo en entornos ambulatorios
Paclaging Device

Transrectal vs. Transperineal

By passing the biopsy needle through the perineum instead of the rectum, the risks associated with the transrectal approach are reduced. The practitioner is not restricted to biopsy locations dictated by a grid configuration, since the technique is freehand. The practitioner can freely manoeuvre the ultrasound probe to align the access needle to target the desired locations with certainty for targeted and systematic biopsies.

PrecisionPoint™ represents a novel approach for urologist to obtain samples in difficult areas of the prostate5 compared to TRUS procedures, through it’s ability to systematically allow access to the whole of the gland.

Centros de formación de la región

BXTA trabaja con urólogos de prestigio, enfermeras clínicas especialistas y líderes de opinión en el campo del diagnóstico de cáncer de próstata para erradicar la biopsia TRUS en pro del LATP como nueva técnica habitual.

Hemos abierto centros de excelencia clínica en varias regiones de Europa, Australia y Nueva Zelanda, como parte del programa de formación internacional diseñado para aumentar el número de asesores, registradores y enfermeras clínicas especialistas formadas en esta nueva técnica avanzada de biopsia de próstata.

Click here to listen to Professor Peter Heathcote discussing options in prostate biopsy

Referencias

  1. Local anaesthetic transperineal biopsy versus transrectal prostate biopsy in prostate cancer detection (TRANSLATE): a multicentre, randomised, controlled trial. Richard J Bryant, Ioana R Marian, Roxanne Williams, J Francisco Lopez, Claudia Mercader, Mutie Raslan, et al. The Lancet Oncology, Volume 26, Issue 5, 583 – 59, 2025.
  2. Is There an Impact of Transperineal Versus Transrectal Magnetic Resonance Imaging-targeted Biopsy in Clinically Significant Prostate Cancer Detection Rate? A Systematic Review and Meta-analysis. Uleri A, Baboudjian M, Tedde A, Gallioli A, Long-Depaquit T, Palou J, et al. Eur Urol Oncol. Dec;6(6):621-628, 2023.
  3. EXIT from TRansrectal prostate biopsies (TREXIT): sepsis rates of transrectal biopsy with rectal swab culture guided antimicrobials versus freehand transperineal biopsy. Newman, T.H., Stroman, L., Hadjipavlou, M. Haque, A., Rusere, J., Chan, K., et al. Prostate Cancer Prostatic Dis 25, 283–287, 2022
  4. Transperineal Magnetic Resonance Imaging-Fusion Targeted Prostate Biopsy Utilizing the PrecisionPoint Transperineal Access System vs a Grid Template: An Assessment of Outcomes. Buller D, Lin F, Wagner J, Antony M, Staff I, McLaughlin T, Tortora J, et al. Urology. 2025
  5. Anterior prostate cancer: is it more difficult to diagnose? Bott SR, Young MP, Kellett MJ, Parkinson MC. BJU Int. Jun;89(9):886-9. 2002

Únase a la conversación

¿Le han diagnosticado cáncer de próstata?

Le agradeceremos que nos dedique 5 minutos de su tiempo para responder a nuestro cuestionario